Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) surged around 16% in premarket trading on Monday after the company reported preliminary fourth-quarter revenue that came in well ahead of analyst forecasts.
The commercial-stage biotechnology company said unaudited fourth-quarter revenue totaled approximately $72 million, up 51% from the same period in 2024 and significantly above the consensus estimate of $59.4 million. For the full year 2025, revenue reached about $277 million, representing 55% year-on-year growth and exceeding analyst expectations of roughly $265 million.
Growth was largely driven by the company’s Minimal Residual Disease (MRD) business. MRD revenue for the fourth quarter rose to approximately $62 million, a 54% increase compared with the prior year. On a full-year basis, MRD revenue climbed 46% to $212 million versus 2024.
Demand for Adaptive’s clonoSEQ testing platform also showed strong momentum. The company delivered around 30,000 tests in the fourth quarter, up 43% year on year. For full-year 2025, total tests delivered reached approximately 105,600, representing a 39% increase from the previous year.
“2025 was a pivotal year for Adaptive, marked by accelerating momentum across our MRD business driven by strong growth in clonoSEQ adoption,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies.
Adaptive reported cash, cash equivalents and marketable securities of approximately $227 million as of December 31, 2025, excluding cash and equivalents held by Digital Biotechnologies, Inc.
The company said it plans to publish its full fourth-quarter and full-year 2025 financial results during its earnings call scheduled for February 2026.